S24. IS IT FEASIBLE TO PREDICT LONG-TERM METABOLIC OUTCOMES IN PSYCHOSIS USING BIOLOGICAL PROFILING AT BASELINE?
Conrad All the predictor categories were included in the initial model, although individual categories were then dropped one at a time. This leave-one-out strategy allowed the direction, impact and relative contribution of the different feature classes to be assessed. Gene-expression and clinical features were consistently associated with the lowest Mean Squared Error after 100 iterations of K-fold cross-validation and after 11 different values of the alpha parameter across 500 imputed datasets. Hba1c or BMI was used as the clinical predictor, depending on whether Hba1c or BMI was used as the target variable. Unattributed surrogate variables derived from surrogate variable analysis (n=6) were analysed within the technical feature set. Having established that gene expression has inherent value as a predictor of metabolic status the same analytical steps were repeated for the discretised versions of these traits (ie. diabetes and obesity). Top-ranking gene transcripts were compared between the quantitative and discretised models. Rank lists of transcripts were subsetted to allow the power distribution across ordered transcripts to be profiled. Discussion: The top performing transcripts identified are undergoing validation analysis in the chronic sample. Results will be conveyed in terms of sensitivity and false positive rates (ie. the area under the Receiver Operating Characteristic curve). We will undertake further validation through trajectory analysis of gene-expression profiles in followed-up patients. Background: Brain-derived neurotrophic factor (BDNF) has been proposed as a biomarker of schizophrenia and, more specifically, as a biomarker of cognitive recovery. Unfortunately, it has only been tested once with cognitive remediation treatment (CRT). Methods: A randomized and controlled trial (NCT02341131) with 70 schizophrenia outpatients and 15 healthy volunteers was conducted. The participants with schizophrenia were randomly assigned to either CRT or the control group. All the participants were assessed in terms of cognition,
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